• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • Fundraising

Financière Arbevel gears up for new life sciences fund first close

Marc Le Bozec of Financiere Arbevel
Marc Le Bozec, Financière Arbevel
  • Myriam Mariotte
  • 07 October 2022
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

French midcap investor Financière Arbevel is set to hold a first close for its new life sciences fund by December, fund manager Marc Le Bozec told Unquote.

Arbevel Life Sciences Crossover II will target EUR 100m and aim for a second close next year.

Investors in the vehicle are all French, with many having already invested in the fund’s predecessor, Arbevel Life Sciences Crossover I, he said. New institutional investors are also expected to join in, including regional entities of French banks.

Fund I was established in 2018 and collected a total of EUR 40m entirely deployed by 2021, Le Bozec said. It invested in health-focused companies with small revenues to support them accelerate sales, he said. It deployed between EUR 1m and EUR 4m in each company, he added.

The fund had the backing of by French LPs and registers around 20% IRR, he said.

Investment plans
Fund II will mainly target pre-revenue companies operating in the French health sector and will focus on medtech along with diagnostic and health services experts, he said.

The Paris-based fund has already identified four potential investments for the vehicle, with the first investments expected before the end of this or year or in 1Q23, Le Bozec said.

ALSC II will be deployed across 12 deals over three years. Its average ticket will be between EUR 8m-10m, he added.

Financière Arbevel mainly invests in minority stakes, Le Bozec said, adding that it plans to have at least one seat on the board of each of its portfolio companies.

It mandates M&A advisors on a case-by-case basis and has worked with Jones Day, EY, White & Case, Lazard and Edmond de Rothschild among others in the past, Le Bozec said.

Fund II plans to exit companies after four to five years, aiming for 2-3x times money minimum when exiting, he said.

During its investment period, the firm will help companies with a low valuation to achieve higher financial status in order to later be able to partner with growth investors such as Apax, KKR or Ardian, he said.

Exits
Financière Arbevel is currently working on three Fund I exits, Le Bozec said, declining to give further details. The vehicles aims to sell for 2-5x times money on average, he added.

This summer, TransCure bioServices, a contract research organization (CRO) specialised in full human immune system and hu-liver mouse models backed by Financière Arbevel in a EUR 2.5m deal in 2019, received an investment from French private equity firm Cathay Capital.

Fund I also invested in NH TherAguix, a French biotechnology company specialised in nanomedicine for cancer radiotherapy treatment. It plans to reinvest when the company will complete its upcoming EUR 40m Series B funding round, as reported.

Established in 1997, Financière Arbevel was acquired by its current management, chairman Jean Baptiste Delabare and CEO Sébastien Lalevée, in 2007. It has around EUR 3.2m under management and 46 employees, including five private equity specialists, Le Bozec said.

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Fundraising
  • Venture
  • Healthcare
  • France
  • Venture
  • France

More on Fundraising

EU foreign subsidies regulations
EU FSR could impact PE fundraising with potential rise in ‘clean funds’

FSR could lead GPs to create funds without foreign LPs; red tape around sovereign wealth funds likely

  • Regulation
  • 01 September 2023
Chris Hitchen of Possible Ventures
VC Profile: Possible Ventures lines up frontier tech deals halfway through fresh EUR 60m fundraise

Germany-based pre-seed investor is set to hold a first close for its third fund in mid-September

  • GPs
  • 25 August 2023
Direct lending funds
Hayfin exceeds EUR 6bn target for fourth direct lending fund

Firm expects to raise EUR 7bn by year-end as it gears up to meet growing private credit demand in Europe

  • Fundraising
  • 18 August 2023
Paris's Arc de Triomphe
Eurazeo co-CEOs seek to reassure market following key departures

Listed GP is also considering options for its stake in Spanish PE platform MCH, it said in its latest results

  • GPs
  • 28 July 2023

Latest News

Fund closes in US dollars
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • 05 September 2023
Clinical trials and biotechnology
  • Buyouts
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • 04 September 2023
Public sector software
  • Exits
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
EMEA Public to Private M&A
  • Investments
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • 04 September 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013